Sanju Varghese, MD
Nephrology · Springfield, OHNPI 1780629956
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $42,975 of the $57,514 with a category attached, or 74.7%. AstraZeneca accounts for 88.2% of it on its own, with 35 other manufacturers making up the rest. Reporting peaked in 2023 at $18,152 and has fallen 73.9% since, to $4,741 in 2025. Among nephrology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 500 payments — averaging $115.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$51K
- Amgen$1K
- Novartis$831
- Bayer$449
- Mallinckrodt Hospital Products Inc.$360
- Akebia Therapeutics Inc$335
- plus $4K from 30 others
Across 10 payments — averaging $2690.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vantive US Healthcare LLC$27K
What the payments were for
- Consulting fees$2,4434%
- Speaking & faculty fees$42,97575%
- Travel & lodging$2,3214%
- Food & beverage$8,92716%
- Education$8491%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$57,514 in reported general payments places this provider in the 95th percentile of 450 nephrology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JynarqueTolvaptan | 13 | $268,957 |
| FarxigaDapagliflozin Propanediol | 192 | $221,545 |
| KerendiaFinerenone | 92 | $86,264 |
| JardianceEmpagliflozin | 61 | $79,094 |
| OzempicSemaglutide | 40 | $37,791 |
| LokelmaSodium Zirconium Cyclosilicate | 38 | $28,910 |
| DapagliflozinDapagliflozin Propanediol | 31 | $14,777 |
| ClinolipidFat Emulsion/Olive/Soy/Phospho | 48 | $12,419 |
| Cinacalcet Hcl | 15 | $10,013 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $9,323 |
| Sevelamer Carbonate | 44 | $4,457 |
| Torsemide | 156 | $4,007 |
| ProsolParenteral Amino Acid 20% No.1 | 29 | $3,579 |
| Potassium Chloride | 182 | $3,319 |
| Metolazone | 110 | $3,067 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Jynarque | $274 | $268,95713 claims |
| AstraZenecaFarxiga, Lokelma | $50,729 | $250,455230 claims |
| BayerKerendia | $449 | $86,26492 claims |
| Boehringer IngelheimJardiance | $179 | $79,09461 claims |
| Novo NordiskOzempic | $207 | $37,79140 claims |
| GSKTrelegy Ellipta | $66 | $9,32311 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $186 | $51321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 450 nephrology providers in Ohio.
Other nephrology in Springfield
- Brad RovinColumbus$379K
- Nissreen ElfadawyChardon$327K
- Andrew LazarBeachwood$315K
- Amit GovilCincinnati$298K
- Georges NakhoulCleveland$255K
- Sankar NavaneethanCleveland$253K
- Ibrahim AhmadKettering$232K
- Prabir Roy ChaudhuryCincinnati$205K
- Rupesh RainaAkron$163K
- Sevag DemirjianCleveland$158K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.